Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes
Journal
Clinical Rheumatology
Journal Volume
36
Journal Issue
9
Pages
1997-2004
Date Issued
2017
Author(s)
Abstract
The aim of the study is to evaluate the long-term outcomes, predictors, and the role of inflammatory cytokines in methotrexate (MTx) refractory juvenile idiopathic arthritis (JIA) patients. This is a retrospective cohort study. MTx refractory JIA patients who received etanercept as their first biological agent in National Taiwan University Hospital (NTUH) were enrolled. Patients were classified into remission group, non-remission group, relapsing group, and non-relapsing group according to the criteria of disease remission and disease flares defined by Wallace et al. We compared the differences in the baseline data, therapeutic responses, time to etanercept tapering, and inflammatory cytokine (IL-12p70, TNF-α, IL-10, IL-6, and IL-1β) levels between these groups. Among the 58 patients, 30 (52%) reached remission. Seventeen of the 30 patients had episodes of disease flares. We found that more patients in the remission group achieved ACR pediatric 70 response at the fourth month after etanercept treatment (p?
SDGs
Other Subjects
C reactive protein; disease modifying antirheumatic drug; etanercept; interleukin 10; interleukin 12p70; interleukin 1beta; interleukin 6; methotrexate; steroid; tumor necrosis factor; antirheumatic agent; cytokine; etanercept; methotrexate; tumor necrosis factor; Article; child; cohort analysis; disease activity; disease exacerbation; drug dose reduction; drug response; erythrocyte sedimentation rate; female; follow up; human; juvenile rheumatoid arthritis; major clinical study; male; morning stiffness; outcome assessment; priority journal; protein blood level; remission; retrospective study; Taiwan; treatment response; antagonists and inhibitors; blood; combination drug therapy; juvenile rheumatoid arthritis; preschool child; proportional hazards model; receiver operating characteristic; recurrent disease; treatment outcome; Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Cytokines; Drug Therapy, Combination; Etanercept; Female; Humans; Male; Methotrexate; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; ROC Curve; Taiwan; Treatment Outcome; Tumor Necrosis Factor-alpha
Publisher
Springer London
Type
journal article